Month: August 2025

Achieves Key Guidance Metrics Reaffirms 2024/2025 Two-Year Adjusted Free Cash Flow guidance TYSONS, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) — TEGNA Inc. (NYSE: TGNA) today announced financial results for the second quarter ended June 30, 2025. “We delivered on our financial commitments this quarter while making important progress on the strategic initiatives that will shape TEGNA’s future, including accelerating our technology roadmap and expanding our local news coverage by 100 hours a day,” said Mike Steib, CEO. “Our focus remains on reinventing how we operate and how we serve our audiences – by investing in local journalism, compelling content, and digital experiences.” “As we announced last year, our Chief Operating Officer, Lynn Beall is retiring on August 31, and I extend my sincere gratitude for her extraordinary leadership...

Outstanding Q4 Contributes to Record Year; Forecasting Growth in FY26 CLEVELAND, Aug. 07, 2025 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the quarter and fiscal year ended June 30, 2025, that included the following highlights (compared with the prior year period): Fiscal 2025 Fourth Quarter Highlights:Sales were a record $5.2 billion; organic sales growth was 2% Net income was $923 million, an increase of 18%, or $992 million adjusted, an increase of 12% EPS were $7.15, an increase of 19%, or a record $7.69 adjusted, an increase of 14% Segment operating margin was 23.9%, an increase of 170 bps, or 26.9% adjusted, an increase of 160 bps Repurchased $851 million of shares Announced agreement to acquire Curtis Instruments, Inc., expanding...

LOWELL, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal third quarter ended July 4, 2025. Third Quarter Fiscal Year 2025 GAAP ResultsRevenue was $252.1 million, an increase of 32.3%, compared to $190.5 million in the previous year fiscal third quarter and an increase of 6.9% compared to $235.9 million in the prior fiscal quarter; Gross margin was 55.3%, compared to 53.2% in the previous year fiscal third quarter and 55.2% in the prior fiscal quarter; Income from operations was $37.7 million, or 14.9% of revenue, compared to income from operations of $19.7 million, or 10.4% of revenue, in the previous year fiscal third quarter and income from operations of $34.9 million,...

– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million – – Ended Q2’25 with Cash, Cash Equivalents and Marketable Securities of $222.2 Million – – Board of Directors Authorized $150 Million Share Repurchase Program – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported...

INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025 Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV) were favorable, with Staidson expecting Phase 3 study initiation InflaRx working diligently toward unblinding of stopped Phase 3 pyoderma gangrenosum (PG) trial so that all data can be analyzed later this year Enrollment began in BARDA funded JUST BREATHE Phase 2 platform clinical trial investigating vilobelimab and additional novel therapeutic candidates for acute respiratory distress syndrome (ARDS) Cash, cash equivalents and marketable securities totaled €53.7 million on June 30, 2025 InflaRx estimates it has sufficient funds for currently planned operations...

Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025 Exploring partnership opportunities to advance pivotal development of silevertinib in NSCLC and GBM Plan to meet with FDA regarding 1L NSCLC development path in 1H 2026, when PFS data becomes available Cash, cash equivalents, and investments of $142.8 million as of June 30, 2025; expected to be sufficient to fund operations into Q4 of 2027CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided...

Achieved record-high quarterly revenues since inceptionIncreased 2025 financial guidance MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q2-25 Highlights Financial resultsRevenues were $107,358, an increase of $11,785 or 12% over the same period in prior year. Gross margin was $44,831 or 42% of revenues compared to $47,337 or 50% of revenues in the same period in prior year. The decrease was mainly driven by the impact of the hyperinflation accounting in Argentina. Operating loss was $3,669 compared...

– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from over 70 clinical sites as of July 31, 2025, with expansion phase enrollment continuing – – FDA meetings to align on the next wave of registrational cohorts for rese-cel anticipated in 3Q25 for lupus, 4Q25 for systemic sclerosis and 1H26 for myasthenia gravis – – Rese-cel clinical data presented at the EULAR 2025 Congress reinforce compelling clinical responses with nearly all patients off immunomodulatory medications and steroids; favorable risk-benefit profile observed across myositis, lupus and systemic sclerosis patients – – Closed $100 million public offering to support late clinical-stage...

TROY, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the second quarter of 2025.Q2 revenue of $1.1 billion, up 4.2% year-over-year reflecting previously disclosed acquisitions, and down 3.3% on an organic basis Q2 operating earnings of $22.2 million; $24.6 million on an adjusted basis, down 12.1% versus the prior year period Q2 adjusted EBITDA of $37.0 million, down 8.7% versus the prior year; adjusted EBITDA margin decreased 40 basis points (“bps”) to 3.4% Company expects year-over-year revenue decline of 5% to 7% in Q3 driven by reduced demand for U.S. federal contractors and from certain large customers. Adjusted EBITDA margin expansion of 80 to 90 bps is expected in Q3 and modest year-over-year margin improvement for the full...

Conference Call Scheduled for 8:30 AM EDT Today, August 7, 2025 SEATTLE and VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for second quarter 2025. “This quarter represents a significant step forward for Achieve. After years of focused dedication, we’ve reached the major milestone of submitting our NDA for cytisinicline, established an innovative commercialization partnership with Omnicom, and secured financing to advance our vision,” said Rick Stewart, Chief Executive Officer of Achieve Life Sciences. “By combining our evidenced-based science with an agile,...